Studies of TKI with blinatumomab for adult Ph+ ALL
Study . | Regimen . | N . | Age, median (range), y . | CR, % . | DFS, % (time) . | OS, % (time) . |
---|---|---|---|---|---|---|
Published/presented | ||||||
GIMEMA D-ALBA19 | Dasatinib, corticosteroids, blinatumomab | 63 | 54 (24-82) | 98 | 88 (18 mo) | 95 (18 mo) |
SWOG 131850 | Dasatinib, corticosteroids, blinatumomab | 25 | 73 (62-87) | 92 | 80 (3 y) | 85 (3 y) |
MDACC51 | Ponatinib, blinatumomab | 35 | 57 (22-83) | 96 | 93 (2 y) | 93 (2 y) |
Ongoing | ||||||
EA9181 (NCT04530565) | Dasatinib or ponatinib/blinatumomab vs dasatinib or ponatinib/HyperCVAD | 330* | (18-75)† | — | — | — |
GIMEMA ALL2820 (NCT04722848) | Ponatinib/blinatumomab vs imatinib/chemotherapy | 236* | (18 and older)† | — | — | — |
Study . | Regimen . | N . | Age, median (range), y . | CR, % . | DFS, % (time) . | OS, % (time) . |
---|---|---|---|---|---|---|
Published/presented | ||||||
GIMEMA D-ALBA19 | Dasatinib, corticosteroids, blinatumomab | 63 | 54 (24-82) | 98 | 88 (18 mo) | 95 (18 mo) |
SWOG 131850 | Dasatinib, corticosteroids, blinatumomab | 25 | 73 (62-87) | 92 | 80 (3 y) | 85 (3 y) |
MDACC51 | Ponatinib, blinatumomab | 35 | 57 (22-83) | 96 | 93 (2 y) | 93 (2 y) |
Ongoing | ||||||
EA9181 (NCT04530565) | Dasatinib or ponatinib/blinatumomab vs dasatinib or ponatinib/HyperCVAD | 330* | (18-75)† | — | — | — |
GIMEMA ALL2820 (NCT04722848) | Ponatinib/blinatumomab vs imatinib/chemotherapy | 236* | (18 and older)† | — | — | — |